Radioimmunoconjugates for treating cancer: recent advances and current opportunities
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Radioimmunoconjugates for treating cancer: recent advances and current opportunities
Authors
Keywords
-
Journal
EXPERT OPINION ON BIOLOGICAL THERAPY
Volume 17, Issue 7, Pages 813-819
Publisher
Informa UK Limited
Online
2017-04-25
DOI
10.1080/14712598.2017.1322577
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Consolidation anti-CD22 fractionated radioimmunotherapy with 90Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trial
- (2017) Françoise Kraeber-Bodere et al. Lancet Haematology
- Development of Lu-177-trastuzumab for radioimmunotherapy of HER2 expressing breast cancer and its feasibility assessment in breast cancer patients
- (2016) Priya Bhusari et al. INTERNATIONAL JOURNAL OF CANCER
- Immuno-PET Using Anticarcinoembryonic Antigen Bispecific Antibody and 68Ga-Labeled Peptide in Metastatic Medullary Thyroid Carcinoma: Clinical Optimization of the Pretargeting Parameters in a First-in-Human Trial
- (2016) C. Bodet-Milin et al. JOURNAL OF NUCLEAR MEDICINE
- MP50-19 DOSE-FRACTIONATED ANTI-PSMA RADIOIMMUNOTHERAPY ( 177 LU-J591) FOR MCRPC
- (2016) Jaspreet S. Batra et al. JOURNAL OF UROLOGY
- Development and preclinical studies of 64Cu-NOTA-pertuzumab F(ab′)2 for imaging changes in tumor HER2 expression associated with response to trastuzumab by PET/CT
- (2016) Karen Lam et al. mAbs
- High-Resolution PET Imaging with Therapeutic Antibody-based PD-1/PD-L1 Checkpoint Tracers
- (2016) Michael Hettich et al. Theranostics
- World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015
- (2016) Shelley McGuire Advances in Nutrition
- Synthesis and Preclinical Evaluation of177Lu-CHX-A”-DTPA-Rituximab as a Radioimmunotherapeutic Agent for Non-Hodgkin's Lymphoma
- (2015) Mythili Kameswaran et al. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
- Combining α-Radioimmunotherapy and Adoptive T Cell Therapy to Potentiate Tumor Destruction
- (2015) Jérémie Ménager et al. PLoS One
- 18F-FDG PET predicts survival after pretargeted radioimmunotherapy in patients with progressive metastatic medullary thyroid carcinoma
- (2014) Pierre-Yves Salaun et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Quantitative ImmunoPET of Prostate Cancer Xenografts with 89Zr- and 124I-Labeled Anti-PSCA A11 Minibody
- (2014) S. M. Knowles et al. JOURNAL OF NUCLEAR MEDICINE
- Phase 1 study of radiosensitization using bortezomib in patients with relapsed non-Hodgkin lymphoma receiving radioimmunotherapy with131I-tositumomab
- (2014) Rebecca L. Elstrom et al. LEUKEMIA & LYMPHOMA
- Gallium-68-Labeled Anti-HER2 Single-Chain Fv Fragment: Development and In Vivo Monitoring of HER2 Expression
- (2014) Masashi Ueda et al. MOLECULAR IMAGING AND BIOLOGY
- Phase II Study of Lutetium-177-Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Metastatic Castration-Resistant Prostate Cancer
- (2013) S. T. Tagawa et al. CLINICAL CANCER RESEARCH
- Fractionated90Y-Ibritumomab Tiuxetan Radioimmunotherapy As an Initial Therapy of Follicular Lymphoma: An International Phase II Study in Patients Requiring Treatment According to GELF/BNLI Criteria
- (2013) Tim M. Illidge et al. JOURNAL OF CLINICAL ONCOLOGY
- Functional Imaging of Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Using 64Cu-DOTA-Trastuzumab PET
- (2013) J. E. Mortimer et al. JOURNAL OF NUCLEAR MEDICINE
- 90Yttrium-Ibritumomab-Tiuxetan as First-Line Treatment for Follicular Lymphoma: 30 Months of Follow-Up Data From an International Multicenter Phase II Clinical Trial
- (2012) Christian W. Scholz et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Anticarcinoembryonic Antigen Pretargeted Radioimmunotherapy in Progressive Metastatic Medullary Thyroid Carcinoma: Biomarker Response and Survival Improvement
- (2012) P.-Y. Salaun et al. JOURNAL OF NUCLEAR MEDICINE
- Combined-modality radioimmunotherapy: synergistic effect of paclitaxel and additive effect of bevacizumab
- (2011) Beom-Su Jang et al. NUCLEAR MEDICINE AND BIOLOGY
- Biodistribution Mechanisms of Therapeutic Monoclonal Antibodies in Health and Disease
- (2009) Mohammad Tabrizi et al. AAPS Journal
- Glomerular Filtration Rate After Alpha-Radioimmunotherapy with 211At-MX35-F(ab′)2: A Long-Term Study of Renal Function in Nude Mice
- (2009) Tom Bäck et al. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
- Intraperitoneal -Particle Radioimmunotherapy of Ovarian Cancer Patients: Pharmacokinetics and Dosimetry of 211At-MX35 F(ab')2--A Phase I Study
- (2009) H. Andersson et al. JOURNAL OF NUCLEAR MEDICINE
- Antibody tumor penetration: Transport opposed by systemic and antigen-mediated clearance
- (2008) Greg M. Thurber et al. ADVANCED DRUG DELIVERY REVIEWS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started